Cause-specific mortality in women receiving hormone replacement therapy

Epidemiology

Volumn 8, Issue 1, 1997, Pages 59-65

  Schairer, Catherine ^a   Adami, Hans Olov ^b   Hoover, Robert ^a   Persson, Ingemar ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

all cause and specific cause mortality; cohort study; hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTRONE SULFATE; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DEATH; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SWEDEN;

EID: 0031012280     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199701000-00010     Document Type: Article

References (37)

1. Judd HL, Meldrum DR, Deftos LJ, Henderson BE. Estrogen replacement therapy: indications and complications. Ann Intern Med 1983;98:195-205.
2. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
3. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:80-104.
4. Persson I, Adami H-O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-151.
5. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989:321:293-297.
6. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
7. Whitehead MI, Lobo RA. Progestagen use in postmenopausal women. Lancet 1988;2:1243-1244.
8. Petitti DB, Perlman JA, Sidney S. Non-contraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek study. Obstet Gynecol 1987;70:289-293.
9. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1084-1086.
10. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program Follow-up Study. JAMA 1983;249:903-906.
11. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality: results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128: 606-614.
12. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
13. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-1109.
14. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325:756-762.
15. Wolf PH, Madan JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease related mortality among post menopausal women who used hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-494.
16. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297:519-522.
17. Adami H-O, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833-839.
18. Persson I, Yuen J, Bergkvist L, Adami H-O, Hoover R, Schairer C. Combined oestrogen-progestagen replacement therapy and breast cancer risk (Letter). Lancet 1992;340:8826.
19. Naessen T, Persson I, Adami H-O, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
20. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99: 821-828.
21. Falkeborn M, Persson I, Terent A, Adami H-O, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153:1201-1209.
22. Persson I, Adami H-O, Bergstrom R, Krusemo UB, Hoover R. Survival in women receiving hormone replacement therapy: a record-linkage study of 6 large population-based cohorts. J Clin Epidemiol 1990;43:677-686.
23. Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami H-O. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for "healthy drug-user" effect. Cancer Causes Control 1993;4:369-374.
24. Persson I, Adami H-O, Johansson E, Lindberg B, Manell P, Westerholm B. A cohort study of estrogen treatment and the risk of endometrial cancer. Evaluation of the method and its applicability. Eur J Clin Pharmacol 1983;25:625-632.
25. Persson I, Adami H-O, Lindberg BS, Johansson EDB, Manell P. Practice and pattern of estrogen treatment in climacteric women in a Swedish population: a descriptive epidemiological study. Part I. Acta Obstet Gynecol Scand 1983;62:289-296.
26. Persson I, Adami H-O, Lindberg BS, Johansson EDB, Manell P. Characteristics of estrogen treated women: a descriptive epidemiological study of a Swedish population. Part II. Acta Obstet Gynecol Scand 1983;62:297-302.
27. Powers MS, Schenkel L, Darley PE, Good WK, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of trans-dermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152:1099.
28. Englund DE, Elamsson KB, Johansson ED. Bioavailability of oestriol. Acta Endocrinol 1982;99:136-140.
29. Causes of Death 1986: Official Statistics of Sweden. Stockholm: National Central Bureau of Statistics, 1988.
30. Breslow NE, Day NE. Statistical Methods in Cancer Research. vol. 2. The Design and Analysis of Cohort Studies. IARC Scientific Pub. No. 82. Lyon: International Agency for Research on Cancer, 1987.
31. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128-1132.
32. Barrett-Connor E, Bush TL. Estrogen use and myocardial infection risk: a case-control study. Prev Med 1984;3:510-516.
33. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-456.
34. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6:227-231.
35. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
36. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
37. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995;38:223-242.